시장보고서
상품코드
1888629

유방암 영상 진단 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 치료 단계별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Breast Cancer Imaging Market Size, Share & Trends Analysis Report By Stage of Care (Diagnostic, Monitoring), By End Use (Hospitals, Breast Care Centers), By Technology, By Region, And Segment Forecasts, 2025 - 2033

발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 140 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

유방암 영상 진단 시장 요약

세계의 유방암 영상 진단 시장 규모는 2024년에 21억 달러로 추정되며, 2033년까지 40억 달러에 달할 것으로 예측됩니다.

2025-2033년 CAGR 7.7%로 성장할 것으로 예상됩니다. 이러한 성장은 유방암에 대한 인식 증가, 기술 발전, 발병률 증가, 정부 및 의료 분야의 노력 확대에 기인합니다. 유방암은 전 세계적으로 여성에게 가장 흔한 암종입니다.

미국에서만 2025년 약 31만 6,950명의 여성이 침윤성 유방암 진단을 받을 것으로 예상되며, 비침윤성 질환인 비침윤성유관상피내암(DCIS)도 5만 9,080건의 새로운 사례가 발생할 것으로 예상됩니다. 이러한 추세는 더욱 가속화될 것으로 예상되며, 예를 들어 '란셋 온콜로지(Lancet Oncology)'지의 한 기사는 2050년까지 전 세계 유방암 발생률은 38%, 관련 사망률은 68% 증가할 것이라며 조기 발견과 추적 관찰의 필요성을 강조하고 있습니다.

미국에서 유방암은 여성에게 두 번째로 많이 발생하는 암이며, 암으로 인한 사망 원인 중 두 번째로 많은 질환입니다. 세계 유방암 증가 요인으로는 BRCA1, BRCA2 돌연변이와 같은 유전적 위험요인 외에도 비만, 부적절한 식습관, 운동부족, 흡연, 음주와 같은 생활습관 요인을 들 수 있습니다. 이러한 심각한 상황 속에서 유방암 사망률 감소와 전 세계 유방암 환자 증가에 대응하기 위해서는 효과적인 유방암 영상 진단 기술을 통한 신속한 진단 지원, 정확한 질병 경과 평가, 환자 예후 개선이 시급한 과제로 대두되고 있습니다.

기술의 발전도 시장을 견인하는 요인으로 진단 방법의 개선에 대한 수요를 창출하고 있습니다. 유방촬영술과 같은 전통적인 방법이 유방암 검진의 근간을 이루는 반면, 새로운 기술은 현재 고위험군이나 고밀도 유방 조직에 대해 이러한 방법을 보완하고 있습니다. 예를 들어, 토모신세시스(3D 맘모그래피)는 유방조직의 중첩으로 인한 아티팩트를 줄여 암 발견율을 30-40% 향상시키고 재검사율을 감소시키고 있습니다. 조영제를 이용한 스펙트럼 유방촬영술(CESM)은 요오드 조영제를 이용하여 유방 내 종양 혈관 구조를 가시화합니다. 유관내암, 소엽암 및 잠재적 병변에 대해서는 유방 MRI와 동등한 진단 정확도를 발휘합니다. 또한, 자동화된 3D 초음파 검사는 재현성을 향상시켜 유방촬영술로 발견하기 어려운 암을 발견할 수 있습니다. 조영초음파검사(CEUS)는 마이크로 버블을 이용하여 CESM과 마찬가지로 종양 혈관 구조의 검출 정확도를 높입니다.

또한, 정부와 의료계의 노력은 조기 발견 개선, 검진 접근성 확보, 기술 혁신의 촉진을 통해 여러 분야에서 유방암 영상 진단의 성장에 기여하고 있습니다. 예를 들어, 인도 정부의 국가보건임무(NHM)는 유방암 퇴치를 위한 여러 국가 프로그램을 발표했습니다. 이 프로그램에는 Ayushman Arogya Mandirs(Ayushman Arogya Mandirs)에서 30세 이상 여성을 대상으로 하는 종합적인 유방암 검진이 포함되어 있으며, 지금까지 1,400만 명 이상의 여성들이 유방암 검진을 받았습니다. 또한 정부는 3차 의료 수준의 암 치료를 개선하기 위해 19개의 주립 암 연구소와 20개의 3차 암 치료 센터의 설립을 승인했습니다. 마찬가지로 미국에서는 무보험 또는 저보험 여성을 대상으로 무료 또는 저렴한 비용으로 유방암 및 자궁경부암 검진 및 진단 서비스를 제공하는 '전국 유방암 및 자궁경부암 조기발견 프로그램(NBCCEDP)'을 시행하고 있습니다. 또한 질병 관리본부(CDC)는 공공기관, 비영리단체, 민간 파트너와 협력하여 45세 미만 여성의 유방암 대책(예방, 조기발견, 인식개선 활동)에 힘쓰고 있습니다. 또한, 영국 정부는 유방암 검진 프로그램을 시작하여 50-71세의 모든 여성에게 3년마다 유방암 검진을 받으라고 권고하고 있습니다. 국가보건서비스(NHS) 유방암 검진 프로그램은 여성들이 검진 선택에 대한 의사결정에 있어 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다. 이러한 정부 및 의료계 주도의 개입 시스템이 결합되어 유방암 영상 진단을 발전시키고, 전 세계 환자들에게 더 빠른 진단과 좋은 치료 결과를 제공할 수 있는 기술에 대한 수요를 불러일으키고 있습니다.

자주 묻는 질문

  • 유방암 영상 진단 시장 규모는 어떻게 예측되나요?
  • 유방암 진단에 대한 미국 내 예측은 어떻게 되나요?
  • 유방암 영상 진단 기술의 발전은 어떤 영향을 미치고 있나요?
  • 정부와 의료계의 유방암 영상 진단에 대한 노력은 무엇인가요?
  • 유방암 영상 진단 시장의 주요 기업은 어디인가요?

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 유방암 영상 진단 시장 변수, 동향, 범위

  • 시장 계통 전망
    • 상부 시장 전망
    • 관련·보조 시장 전망
  • 시장 역학
  • 유방암 영상 진단 시장 분석 툴
    • 업계 분석 : Porter's Five Forces
    • PESTEL 분석

제4장 유방암 영상 진단 시장 : 기술 추정·동향 분석

  • 유방암 영상 진단 시장 : 기술 변동 분석
  • 유방암 영상 진단 시장 : 기술별 전망
  • 시장 규모 및 예측 및 동향 분석(2021-2033년)
  • 맘모그래피 시스템(2D, 3D)
  • 자기공명영상법(MRI) 기반 시스템
  • 핵의학 기반 시스템
  • 초음파 기반 시스템
  • 영상 유도하 생검
  • 기타

제5장 유방암 영상 진단 시장 : 치료 단계 추정·동향 분석

  • 유방암 영상 진단 시장 : 치료 단계 변동 분석
  • 유방암 영상 진단 시장 : 치료 단계별 전망
  • 시장 규모 및 예측 및 동향 분석(2021-2033년)
  • 진단
  • 치료전 계획
  • 모니터링
  • 경과 관찰(팔로업)

제6장 유방암 영상 진단 시장 : 최종 용도 추정·동향 분석

  • 유방암 영상 진단 시장 : 최종 용도 변동 분석
  • 유방암 영상 진단 시장 : 최종 용도별 전망
  • 시장 규모 및 예측 및 동향 분석(2021-2033년)
  • 병원
  • 진단 영상 센터
  • 유방암 케어 센터
  • 기타

제7장 유방암 영상 진단 시장 : 지역 추정·동향 분석

  • 지역별 대시보드
  • 지역별 유방암 영상 진단 시장 변동 분석
  • 유방암 영상 진단 시장 : 지역 추정·동향 분석 : 기술별, 최종 용도별
  • 시장 규모 및 예측 및 동향 분석(2021-2033년)
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 스웨덴
    • 노르웨이
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 한국
    • 호주
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트

제8장 경쟁 구도

  • 시장 진입 기업 분류
  • 주요 기업 개요
    • GE Healthcare
    • Hologic Inc.
    • Siemens Healthcare
    • Philips Healthcare
    • Delphinus Medical Technologies
    • Trivitron Healthineers
    • Aurora Imaging Technology Inc.
    • Micrima Limited
    • QT Ultrasound LLC
    • Fujifilm
KSM 25.12.26

Breast Cancer Imaging Market Summary

The global breast cancer imaging market size was estimated at USD 2.1 billion in 2024 and is projected to reach USD 4.0 billion by 2033, growing at a CAGR of 7.7% from 2025 to 2033. This growth is attributed to increasing breast cancer awareness, technological advancements, rising incidence rates, and growing government and healthcare initiatives. Breast cancer is the most common type of cancer among women globally.

In the U.S. alone, an estimated 316,950 women are expected to be diagnosed with invasive breast cancer in 2025, along with 59,080 new cases of ductal carcinoma in situ (DCIS), a non-invasive form of the disease. This tendency is forecasted to escalate, for instance, the article by the Lancet Oncology states that global breast cancer incidence is expected to increase by 38% and related deaths by 68% by 2050, highlighting the need for early detection and tracking.

In the U.S., breast cancer is the second most common cancer and the second most common cause of cancer death among women. Contributing factors to the global rise of breast cancer include genetic risk factors, like the BRCA1 and BRCA2 mutations, and lifestyle factors like obesity, poor diet, sedentary lifestyle, smoking, and alcohol consumption. With the escalating severity of this situation, there is an urgent need for effective breast cancer imaging technologies to support timely diagnosis, assess the disease process accurately, and improve patient outcomes, which are crucial for reducing breast cancer mortality rates and managing the global rise in cases.

Technological advancement is another driving factor for the market, leading to a demand for improved diagnostic modalities. While traditional methods like mammography have been the foundation for breast cancer screening, emerging technologies are now complementing these approaches for high-risk populations and dense breast tissue. For example, tomosynthesis (3D mammography) has reduced breast tissue overlap artifacts, increasing cancer detection by 30-40% and decreasing recall rates. Contrast-enhanced spectral mammography (CESM) uses iodine contrast to visualize tumor vascularization in the breast. It performs with diagnostic accuracy like breast MRI for intraductal and lobular carcinomas and for occult lesions. In addition, automated 3D ultrasounds improve reproducibility and detect mammographically occult cancers. Contrast-enhanced ultrasound (CEUS) utilizes microbubbles to enhance the detection of tumor vascularity, similarly to CESM.

In addition, Government and healthcare initiatives contribute to the growth of breast cancer imaging in multiple areas, especially by improving early detection, ensuring screening access, and driving technological innovation. For instance, the National Health Mission (NHM) by the Indian government announced several national programs aimed at tackling breast cancer. The program includes comprehensive breast screening for individuals aged 30+, at Ayushman Arogya Mandirs, with over 14 crore women screened for breast cancer sc. Moreover, the government has approved the establishment of 19 state cancer institutes and 20 tertiary cancer care centers to improve tertiary-level cancer care. Similarly, the U.S. has implemented the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) to provide free or low-cost breast and cervical cancer screening and diagnostic services for uninsured or underinsured women. Furthermore, the Centers for Disease Control and Prevention (CDC) collaborates with public, non-profit, and private partners to address breast cancer in women under 45, focusing on prevention, early detection, and education. In addition, the UK government has started a breast screening program, inviting all women aged 50 to 71 to be screened with mammography on a three-yearly basis. The National Health Service Breast Screening Programme supports women in being informed and involved in decision-making around their screening options. These systems of governmental and healthcare-led intervention combine to stimulate demand for technologies that can advance the imaging of breast cancer, thus enabling earlier diagnosis and better outcomes for patients globally.

Global Breast Cancer Imaging Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global breast cancer imaging market report based on technology, stage of care, end-use, and region:

  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Mammography System (2D,3D)
  • Magnetic Resonance Imaging (MRI)-based systems
  • Nuclear Medicine- Based Systems
  • Ultrasound-Based Systems
  • Image-guided Biopsy
  • Others
  • Stage of Care Outlook (Revenue, USD Million, 2021 - 2033)
  • Diagnostics
  • Pre-treatment Planning
  • Monitoring
  • Surveillance (Follow-Up)
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic Imaging Centers
  • Breast Care Centers
  • Others
  • Region Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Stage of Care
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Stage of Care outlook
    • 2.2.3. End Use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Breast Cancer Imaging Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Incidence of Breast Cancer
      • 3.2.1.2. Technological Advancements
      • 3.2.1.3. Increasing Government and Healthcare Initiatives
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Equipment Costs
      • 3.2.2.2. Limited Health Care Access
  • 3.3. Breast Cancer Imaging Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Breast Cancer Imaging Market: Technology Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Breast Cancer Imaging Market: Technology Movement Analysis
  • 4.3. Breast Cancer Imaging Market by Technology Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
  • 4.5. Mammography System (2D,3D)
    • 4.5.1. Mammography System (2D,3D) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Magnetic Resonance Imaging (MRI)-based Systems
    • 4.6.1. Magnetic Resonance Imaging (MRI)-based Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Nuclear Medicine- Based Systems
    • 4.7.1. Nuclear Medicine-Based Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Ultrasound-Based Systems
    • 4.8.1. Ultrasound-Based Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.9. Image-guided Biopsy
    • 4.9.1. Image-guided Biopsy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Breast Cancer Imaging Market: Stage of Care Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Breast Cancer Imaging Market: Stage of Care Movement Analysis
  • 5.3. Breast Cancer Imaging Market by Stage of Care Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
  • 5.5. Diagnostics
    • 5.5.1. Diagnostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Pre-treatment Planning
    • 5.6.1. Pre-treatment Planning Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Monitoring
    • 5.7.1. Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Surveillance (Follow-Up)
    • 5.8.1. Surveillance (Follow-Up) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Breast Cancer Imaging Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Breast Cancer Imaging Market: End Use Movement Analysis
  • 6.3. Breast Cancer Imaging Market by End Use Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
  • 6.5. Hospitals
    • 6.5.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Diagnostic Imaging Centers
    • 6.6.1. Diagnostic Imaging Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Breast Care Centers
    • 6.7.1. Breast Care Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Breast Cancer Imaging Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Regional Breast Cancer Imaging Market Movement Analysis
  • 7.3. Breast Cancer Imaging Market: Regional Estimates & Trend Analysis by Technology & End Use
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
  • 7.5. North America
    • 7.5.1. North America Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. U.S.
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement scenario
      • 7.5.2.5. U.S. Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Canada
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement scenario
      • 7.5.3.5. Canada Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. Mexico
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement scenario
      • 7.5.4.5. Mexico Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Europe
    • 7.6.1. Europe Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. UK
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement scenario
      • 7.6.2.5. UK Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Germany
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement scenario
      • 7.6.3.5. Germany Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. France
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement scenario
      • 7.6.4.5. France Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Italy
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement scenario
      • 7.6.5.5. Italy Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. Spain
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement scenario
      • 7.6.6.5. Spain Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Denmark
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement scenario
      • 7.6.7.5. Denmark Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.8. Sweden
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Competitive Scenario
      • 7.6.8.3. Regulatory Framework
      • 7.6.8.4. Reimbursement scenario
      • 7.6.8.5. Sweden Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.9. Norway
      • 7.6.9.1. Key Country Dynamics
      • 7.6.9.2. Competitive Scenario
      • 7.6.9.3. Regulatory Framework
      • 7.6.9.4. Reimbursement scenario
      • 7.6.9.5. Norway Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Asia Pacific Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Japan
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement scenario
      • 7.7.2.5. Japan Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. China
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement scenario
      • 7.7.3.5. China Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. India
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. Reimbursement scenario
      • 7.7.4.5. India Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Reimbursement scenario
      • 7.7.5.5. South Korea Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.6. Australia
      • 7.7.6.1. Key Country Dynamics
      • 7.7.6.2. Competitive Scenario
      • 7.7.6.3. Regulatory Framework
      • 7.7.6.4. Reimbursement scenario
      • 7.7.6.5. Australia Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.7. Thailand
      • 7.7.7.1. Key Country Dynamics
      • 7.7.7.2. Competitive Scenario
      • 7.7.7.3. Regulatory Framework
      • 7.7.7.4. Reimbursement scenario
      • 7.7.7.5. Thailand Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Latin America Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. Brazil
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement scenario
      • 7.8.2.5. Brazil Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement scenario
      • 7.8.3.5. Argentina Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9. Middle East & Africa
    • 7.9.1. Middle East & Africa Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.2. South Africa
      • 7.9.2.1. Key Country Dynamics
      • 7.9.2.2. Competitive Scenario
      • 7.9.2.3. Regulatory Framework
      • 7.9.2.4. Reimbursement scenario
      • 7.9.2.5. South Africa Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.3. Saudi Arabia
      • 7.9.3.1. Key Country Dynamics
      • 7.9.3.2. Competitive Scenario
      • 7.9.3.3. Regulatory Framework
      • 7.9.3.4. Reimbursement scenario
      • 7.9.3.5. Saudi Arabia Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.4. UAE
      • 7.9.4.1. Key Country Dynamics
      • 7.9.4.2. Competitive Scenario
      • 7.9.4.3. Regulatory Framework
      • 7.9.4.4. Reimbursement scenario
      • 7.9.4.5. UAE Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.5. Kuwait
      • 7.9.5.1. Key Country Dynamics
      • 7.9.5.2. Competitive Scenario
      • 7.9.5.3. Regulatory Framework
      • 7.9.5.4. Reimbursement scenario
      • 7.9.5.5. Kuwait Breast Cancer Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Key Company Profiles
    • 8.2.1. GE Healthcare
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Hologic Inc.
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Siemens Healthcare
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Philips Healthcare
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Delphinus Medical Technologies
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Trivitron Healthineers
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Aurora Imaging Technology Inc.
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Micrima Limited
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. QT Ultrasound LLC
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Fujifilm
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제